Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Guardian - UK

Sanders targets ‘unacceptable’ price of weight-loss drugs Ozempic and Wegovy

Vermont senator will grill CEO of Danish pharma giant whose drugs cost Americans 10 times more than abroad

The Guardian - US

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

The Independent UK

Lawsuit could challenge trust in Ozempic and other popular weight loss drugs

The manufacturers of the most popular weight loss drugs are being challenged in court.

The Conversation

Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month

A fire has broken out at an office building belonging to Danish pharmaceutical company Novo Nordisk, the third in a little over a month to hit the drugmaker

The Independent UK

London women are falling pregnant on Ozempic — but no one knows if it's safe yet

As women in the UK are hit by the great ‘Ozempic pregnancy scare’ sweeping the US, fertility experts warn of its potential risks

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Fall Ahead Of Retail Sales; Nvidia Stock Reverses Lower

Dow Jones futures dropped Tuesday ahead of retail sales data. Nvidia stock reversed lower Monday on the stock market today.

Investors Business Daily

Top Weight-Loss Rivals Share This Risk After Eye-Popping Runs

Investors Business Daily

Dow Jones Falls; Nvidia Stock Reverses From Record Highs

Stock Market Today: The Dow Jones dropped Monday, as the stock market eyed more new highs. Nvidia stock hit new highs, but reversed lower.

Investors Business Daily

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Fortune

Dow Jones Falls 300 Points After Inflation Survey; AI Stock Adobe Soars On Earnings

Stock Market Today: The Dow Jones fell 300 points Friday on a hotter-than-expected inflation survey. AI stock Adobe soared on earnings.

Investors Business Daily

Dow Jones Slides After Inflation Data, Jobless Claims; Tesla Surges On Elon Musk Tweet

Stock Market Today: The Dow Jones industrials dropped on key inflation data Thursday. Tesla stock surged on CEO Elon Musk's tweet.

Investors Business Daily

ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership

Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks

These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.

Al Jazeera

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Investors Business Daily

Obesity Drug Leader In Buy Zone After Huge Gains

Novo Nordisk is in a buy zone after a 39% gain year to date. The anti-obesity drug market is expect to grow to $4.4 billion by 2032.

International Business Times UK

George Soros's Fund Sells Uber, Novo Nordisk in Q1 to Focus on AI, Construction, and Apparel Stocks

Soros Fund Management made several changes to its portfolio in Q1, increasing stakes in Alphabet, Nike, and D.R. Horton.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Netflix, Novo Nordisk And These IPOs Fuel Smorgasbord Of Breakouts

Netflix and Novo Nordisk are just two names on this smorgasbord of stocks setting up or soaring past new buy points.

Investors Business Daily

Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight

As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.

Investors Business Daily

Dow Jones Falls As Warren Buffett Stock 'Plunges' 99%; Bill Ackman Makes This IPO Move

The Dow Jones fell on the stock market today. GameStop surged after influencer "Roaring Kitty" claimed a big stake. AI stock Nvidia popped.

Investors Business Daily

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

The Street

One Ozempic patient reveals major drug-powered weight loss truths

As medicines for losing weight become more widely accessed and affordable, people are discussing their experiences.

The Guardian - UK

Women advised to pair effective contraception with ‘skinny jabs’

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

StockNews.com

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

1 … 4 5 6 7

People

Lars Fruergaard Jørgensen

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.